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Mouse plasma peptide atlas<p>A publicly available repository for high-quality peptide and protein data, identified by LC-MS/MS analysis.</p>
Abstract
We present an in-depth analysis of mouse plasma leading to the development of a publicly available
repository composed of 568 liquid chromatography-tandem mass spectrometry runs. A total of
13,779 distinct peptides have been identified with high confidence. The corresponding
approximately 3,000 proteins are estimated to span a 7 logarithmic range of abundance in plasma.
A major finding from this study is the identification of novel isoforms and transcript variants not
previously predicted from genome analysis.
Background
In-depth analysis of the plasma proteome has the potential to
yield biomarkers that allow early disease detection, and mon-
itoring of disease progression, regression or recurrence.
Mouse models have provided a physiological context in which
to explore various aspects of disease pathogenesis and com-
plement the use of cell line models and tissue sampling
approaches. Genetically engineered mouse models have been
increasingly relied upon to investigate specific molecular
alterations associated with human disease. Recent transcrip-
tional profiling and comparative genomic analyses of human
and mouse cancers have revealed significant concordance in
genomic alterations and expression profiles, thus justifying
reliance on mouse models to identify molecular alterations
and markers potentially relevant to human cancers and other
diseases [1-5].
Genetically engineered mouse models allow investigations of
proteomic changes at defined stages of disease development,
and exhibit reduced heterogeneity, thus providing greater
ease of standardization of blood and tissue sampling and
preparation. However, there has been limited comprehensive
analysis to date of the mouse plasma proteome. Studies of
disease related plasma protein alterations in the mouse will
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that assembles high quality queryable data and that informs
about the extent of protein variation encompassed within the
mouse proteome.
Previous studies of mouse proteomes include a large-scale
study of mouse liver tissue that identified 3,244 proteins [6].
A comparative proteomics study of tumor and normal mam-
mary tissue from a conditional HER2/Neu-driven mouse
model of breast cancer identified changes in tissue proteins
leading to the identification of up-regulated fibulin-2 and
osteopontin in mouse plasma [7]. A study of the plasma pro-
teome in a mouse intestinal tumor model identified a protein
subset that distinguished tumor bearing mice from controls
[8].
We have implemented a proteomic strategy that allows in-
depth analysis of the plasma proteome. We have applied this
to protein digests of fractionated mouse plasma reference
specimens to determine protein and peptide constituents of
mouse plasma and have built a related data repository. A
large number of novel transcript variants for mouse plasma
proteins have been identified. The data are publicly available
at the PeptideAtlas site [9], which can be viewed and
searched. The raw data as well as the search results are also
available for download from the 'Data Repository' page of the
same site.
Results
Identification of 13,779 distinct peptides in mouse 
plasma
Four mouse reference plasma pools were each subjected to
extensive fractionation and separate liquid chromatography-
tandem mass spectrometry (LC-MS/MS) analysis of digests
from individual fractions. The combined four experiments
yielded 800,507 spectra with a PeptideProphet [10] probabil-
ity (P) score of ≥0.9 from a total of 568 LC-MS/MS runs. The
overall false discovery rate for spectrum assignment was cal-
culated to be 1.2% based on PeptideProphet cutoffs. Of the
13,779 distinct peptides with P ≥0.9 encompassed in the anal-
ysis, 13,461 peptides were successfully mapped to the
Ensembl Mouse [11] release 43, which was built on the NCBI
m36 mouse assembly. Of the set of 13,779 distinct peptides,
9,170 (67%) were identified with at least 2 spectra. Cys-con-
taining, Trp-containing, and Lys-containing peptides repre-
sented 3,709 (27%), 2,067 (15%), and 8,392 (61%) of the total
peptides, respectively (Table 1).
The mean peptide length for the 13,779 peptide set was 16,
with a range of 6-49 amino acids. There was a bias in the dis-
tribution of peptide length, which favored relatively long pep-
tides (Figure 1). A similar finding from human proteome
studies was previously reported [12]. The under-representa-
tion of short peptides may result from losses due to reduced
sequence-specific fragment ions, or difficulty in distinguish-
ing them from noise due to low m/z values. The mean molec-
ular weight of this set was approximately 1,750 Da with a
range of 640-4,100 Da. The majority of peptides identified
were either neutral or acidic, with an average pI of approxi-
mately 6. There were 5958, 8874, 7753, and 5368 distinct
peptides identified for the 4 reference sets (Table 1). The
number of peptides identified may relate to variability in pro-
tein levels between reference sets, particularly for abundant
proteins, which affects mass spectrometer peptide sampling
and variability in protein recovery with sample processing.
Identification of 2,982 proteins in mouse plasma using 
ProteinProphet
A combined search of data from all four reference sets was
done using ProteinProphet [13]. This yielded 2,982 distinct
International Protein Index (IPI) identifications correspond-
ing to 2,631 known genes plus 281 hypothetical proteins with
an error rate less than 5%. Among these, 2,131 (71%) proteins
were identified with at least 3 unique peptides, 2,600 (87%)
with at least 2 unique peptides, and 382 with only one unique
peptide (singlets, 13%). Among these singlets, 140 (37%) were
observed only once within the whole study, and thus are likely
the major source of false identifications. Cytoplasmic pro-
teins contributed the most, at approximately 29%; extracellu-
lar, nucleus, and plasma membrane proteins accounted for
17%, 17%, and 14%, respectively, based on ingenuity pathway
analysis [14]. The limited contribution of secreted and surface
membrane proteins to the overall total may be the result of
release through non-secreted pathways and cell turnover. The
tissue distribution and gene expression levels of this set of
proteins was investigated based on the mouse SymAtlas
(Novartis Research Foundation) [15]. The tissue with the
maximum expression for a given gene was assigned to that
particular gene. Approximately 8% of identified proteins had
the highest expression of their corresponding genes repre-
sented by liver (mRNA per gram tissue), which is considered
a major source of abundant plasma proteins. The range of
MS/MS events corresponding to high confidence protein
identifications based on two peptides or more varied between
approximately 50,000 and 2. We previously observed a sig-
nificant correlation between the number of MS/MS events for
a given protein and its plasma protein concentration
(log(MS/MS events) = (0.623 × log(Protein concentration)) +
0.0625) (unpublished data). We infer, therefore, that abun-
dance of mouse plasma proteins identified in this study may
span a logarithmic range of 7.
Occurrence of cleaved protein forms
Proteins undergo numerous post-translational modifica-
tions, notably cleavages in the case of proteins shed into the
circulation. The mouse PeptideAtlas may be queried to
determine the distribution of peptides identified for a given
protein and the occurrence of cleaved forms in particular
fractions. This is illustrated for the epidermal growth factor
receptor (EGFR), which is a single-pass type I membrane pro-
tein [16], as an example of the depth of analysis achieved andGenome Biology 2008, 9:R93
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over-expressed EGFR is of relevance to a number of disease
processes [17]. The trans-membrane region is located at
amino acids 646-668, and the extracellular domain is
between amino acids 25-645 (Figure 2). A total of over 4,000
MS2 events in mouse PeptideAtlas corresponding to EGFR
matched 34 distinct peptides that spanned exclusively the
extracellular domain of the protein, resulting from cleavage
and release of this domain. The PeptideAtlas provides a
graphic interface for protein fragmentation and can be used
as a tool for comparisons between different species. Of inter-
est, one peptide derived from mouse EGFR, PAp00148806
(IPLENLQIIR amino acids 99-108, lab 34), was also identi-
fied in the PeptideAtlas analysis of the Human Proteome
Organization (HUPO) human plasma samples as the mouse
and the human share the same sequence for this peptide [9].
Observed splice isoforms
Approximately 3,000 distinct peptides were identified that
spanned exon boundaries, of which 1,717 were observed at
least twice. Among these, 180 peptides were observed in all 4
mouse plasma pools/experiments, and mapped to proteins
with a unique genome location. The database represents a
useful resource for validation of splice isoforms predicted in
the Ensembl mouse genome. For example, PAp00024736,
with a peptide sequence DQGSCGSCWAFGAVEAISDR, was
mapped to a single protein cathepsin B precursor with a
unique genome location on mouse chromosome 14. This pep-
tide was observed a total of 39 times in multiple fractions and
in all 4 experiments. The first nine amino acids (DQGSCG-
SCW) covered one exon from genome location 62089806 to
62089832, while the rest (AFGAVEAISDR) were located on
another exon at genome location 62090517 to 62090549.
Cathepsin B regulates the hydrolysis of proteins with broad
specificity for peptide bonds [18].
A list of approximately 950 peptides that did not map to any
annotated gene in the mouse genome was developed, with an
overall 1.7% false discovery rate for peptide identification.
These represent putative novel open reading frames. The
majority (61%) had at least two observations. One example is
PAp00438183, with a sequence of RPQMVEGDHGDEIFS-
VFGAPLLK, which was identified over 300 times and in all 4
experiments. The peptide was mapped to a single protein,
Table 1
Summary of peptides identified with a PeptideProphet P score ≥0.9
Peptide Counts Percentage
Total assignment above threshold 800,507
Total correct assignment 791,069
Total incorrect assignment 9,438
Spectrum assignment false discovery rate 0.012
Total distinct peptides 13,779 100.00
Distinct peptides mapped to human genome 13,461 97.69
Possible proteins implicated in mapping 10,674
Simple reduced proteins 4,084
Simple reduced genes 3,580
Unambiguously mapped proteins 1,590
Total distinct peptides, presented in ≥2 samples 9,170 66.55
Total singleton distinct peptides 4,609 33.45
Cys-containing distinct peptides 3,709 26.92
Trp-containing distinct peptides 2,067 15.00
Lys-containing distinct peptides 8,392 60.90
Total distinct peptides from colon cancer versus normal 5,958
Total distinct peptides from breast cancer versus normal 8,874
Total distinct peptides from pancreatic cancer versus normal 7,753
Total distinct peptides from ovarian cancer versus normal 5,368
Total distinct peptides in all four reference sets 2,897 21.02
Total distinct peptides in three reference sets 1,534 11.13
Total distinct peptides in two reference sets 2,415 17.53Genome Biology 2008, 9:R93
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sequence matched to the coding region of this protein on
chromosome 8 with 91% identity.
Identification of novel alternative splice isoforms
Alternative splicing plays a major role in protein diversity
without significantly increasing genome size. Aberrations in
alternative splice variants are known to contribute to a
number of diseases [19]. As highlighted recently in the
Encode project [20], the extent of transcript structural varia-
tion in mammalian genomes has been under-appreciated. To
identify novel splice isoforms that are translated into protein
products, we interrogated the intact protein analysis system
(IPAS; see Materials and methods) data sets using a protein
sequence collection containing the products of both known
and hypothetical transcripts.
A target database with over 10 million sequences was built
upon the ECgene [21] and Ensembl mouse [11] databases as
described in Materials and methods and in Fermin et al. [22].
An extensive computational analysis for a reference set was
done to identify novel forms. Using a X!Tandem expect value
of <1e-3 as a threshold, we identified a total of 12,461 proteins
and 8,154 distinct peptides matching 147,051 spectra in the
target database. Among these, 7,291 distinct peptides (90%)
were in multi-peptide sets and 863 (10%) in single peptide
identification sets. At this threshold, 81 distinct reversed
sequence proteins (0.65%) and 53 reversed sequence pep-
tides (0.65%) matched 69 distinct spectra.
The splice isoforms derived from a gene share exons with
each other. Further, specific peptides may occur in several
members of a paralogous family of proteins. To obtain a
measure of the number of independent protein identifica-
tions, it is necessary to integrate protein identifications into
covering sets (see Materials and methods). To be included in
the integrated protein list, peptide spectral matches need to
be unique and not explained by another protein in the list.
The integrated list for the set of protein identifications includ-
ing novel splice isoform translation products contained a
total of 1,324 distinct proteins. Multiple splice isoforms were
identified for a number of proteins that have been suggested
as potential disease biomarkers in previous studies: Cpn1
(carboxypeptidase N, polypeptide 1), Pzp (pregnancy zone
protein), Fabp5 (fatty acid binding protein 5) and Mbl2 (man-
nose binding lectin) [23]. In selecting proteins to be members
of the covering sets, our algorithm gives preference to anno-
tated protein sequences. Of the integrated 1,324 protein sets,
1058 (80%) were annotated gene products (that is, proteins
in the Ensembl protein collection) and 199 (15%) were found
only in the ECGene collection of novel transcripts. Note that
in many cases, the set of identifications 'covered' by an anno-
tated protein will also contain proteins derived from previ-
ously un-annotated transcripts.
Comparative analysis of mouse and human splice 
isoforms
We examined mouse splice variants identified as homologues
of human counterparts. Similarities were uncovered with
human peptides. A case in point is mouse splice variant
M13C2563_1_s386_e8960_1_rf2_c1_n0, which was identi-
fied with 13 distinct peptides from 19 spectra through the
genomic database search. Peptides LLEAQIATGGIIDPK,
GFFDPNTEENLTYLQLK, and LNDSILQATEQR were identi-
fied by four, three and two spectra, respectively. However,
when all 13 peptides were searched against the NCBI NR
database using the blastp program, 12 peptides matched to a
predicted mouse protein similar to desmoplakin protein. In
contrast, all 13 peptides were found to be homologous to the
human desmoplakin sequence. The alignment of peptide
LLEAQIATGGIIDPK using the UCSC Blast program is shown
in Figure 3. This peptide aligns to the coding sequence of
human desmoplakin, but not to the annotated mouse desmo-
plakin gene. Therefore, our data clarify similarities between
the mouse and the human coding sequences for this gene.
Such detailed analysis of splice variants may identify novel
alternative splicing relevant to disease.
Protein fractionation as a means to characterize splice 
isoform products
When the protein products of alternative splice isoforms dif-
fer in structure, we expect that the physical properties of these
proteins, in particular their fraction location, may vary. Find-
ing evidence for non-neighboring fractions with distinct pep-
tide content for the same protein supports the identification
of multiple products from the same gene. Figure 4 illustrates
Characterization of distinct peptides identified from mouse plasma refe ence setsFigure 1
Characterization of distinct peptides identified from mouse plasma 
reference sets. The histogram of peptide length of unique sequences in 
mouse PeptideAtlas (blue) is overlaid on an in silico tryptic digest of the IPI 
mouse database (black).
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H2 K1 K region antigen. Intact proteins were subjected to
anion exchange (AX) and reverse phase (RP) chromatogra-
phy fractionation in this study. Each fraction was then sub-
jected to tryptic digestion and LC-MS/MS analysis. Figure 4
shows the distribution of peptides derived from this gene
among the AX and RP chromatography fractions. The unique
peptides identified in the major splice isoform and alternative
splice variants were found in separate fractions, consistent
with translation of the different splice isoforms yielding dis-
tinct protein products with distinct physical properties. The
MHC H2 K1 K region gene encodes one of the MHC class 1
antigens, which may be altered in tumors [24].
Pathway annotation of identified mouse plasma 
proteins
To determine whether sufficient depth of analysis was
achieved to identify proteins that are relevant to disease, we
performed ingenuity pathway analysis [14] for 1,058 proteins
that were fully annotated to known proteins. A number of
known genes may be candidate disease biomarkers based on
splice variants. For example, CD44 [25] is a cell-surface
glycoprotein that participates in a variety of cellular func-
tions, including tumor metastasis. Alternative splicing gener-
ates a diverse collection of structurally and functionally
distinct protein products from this gene [14,26,27]. CD44
gene products, consisting of three splice isoforms, are found
in the integrated set of proteins defined by the lead peptide
YGFIEGNVVIPR. This group of 3 splice isoforms was identi-
fied with 3 distinct peptides from 14 spectra in our data set.
All members of this group included all three peptides.
The extracellular matrix protein 1 is another example where
the major splice isoform and two novel alternative splice iso-
forms were found in the integrated list. Extracellular matrix
protein 1 is a secreted protein that has been implicated in cell
proliferation, angiogenesis and differentiation. This protein
is preferentially expressed in epithelial tumors and has been
suggested as a potential cancer biomarker [28].
Discussion
Our study has yielded an in-depth analysis of mouse plasma
resulting in a high quality peptide database built from four
reference pools. The mouse plasma PeptideAtlas currently
contains more than 800,000 spectra corresponding to
Peptide identification and distribution of mouse EGFRFigur 2
Peptide identification and distribution of mouse EGFR. A total of 34 distinct peptides were identified from approximately 4,000 MS2 events. All peptides 
are from the extracellular domain.Genome Biology 2008, 9:R93
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tions are expected from accumulation of new data sets result-
ing from other instrument platforms or sample processing
protocols, other database search algorithms and analysis of
disease models.
The identified proteins span an estimated 7 logarithm range
of abundance encompassing prostate specific antigen, esti-
mated to occur in plasma at approximately 1 ng/ml [29], to
abundant plasma proteins present at 40 mg/ml. The ability to
detect less abundant proteins is highly relevant to biomarker
discovery as most known disease biomarkers occur at low-
abundance in the range of prostate specific antigen. Detection
of low abundance proteins results from a combination of
extensive fractionation of intact proteins using an orthogonal
two-dimensional system of AX and RP chromatography, and
high resolution LC-MS/MS analysis. The methodology also
allows detection of protein cleavage products and splice
isoforms.
Some similarities and some differences between human and
mouse plasma have emerged from our analysis. An extensive
pattern of cleavage of biological significance has been
reported previously for human complement factor C3 [30],
and our data demonstrate similar findings for the mouse. In
contrast, for EGFR, a marked difference in abundance based
on number of spectra was observed between human (10 spec-
tra) and mouse (>4,000), which may be related to differences
in sources of EGFR between mouse and human based on gene
expression analysis [15]. EGFR has the highest expression in
liver in mouse, which is not the case for humans. Alternative
splicing is an important source of protein diversity [31,32],
and deep sampling of the plasma proteome as accomplished
in this study is relevant to the identification of novel splice
isoforms. Variation in the delicately controlled process of
splicing may occur in disease states. Alternative splicing in
cancer has been investigated on a small scale [25]. Proteomic
data as obtained in this study provide a complementary
approach to annotate the genome [33,34], and represent a
useful resource for the discovery of alternatively spliced
forms. We identified novel splice isoforms of known genes as
well as previously un-annotated open reading frames [22]. An
assessment of the relevance of identified splice isoforms as
disease biomarkers would be of interest.
Conclusion
We have developed the mouse plasma PeptideAtlas database,
along with its web interface, as a means for depositing mass
Genomic mapping of mouse peptide LLEAQIATGGIIDPK using UCSC Blast programFigure 3
Genomic mapping of mouse peptide LLEAQIATGGIIDPK using UCSC Blast program. Mouse splice variant M13C2563_1_s386_e8960_1_rf2_c1_n0 was 
identified with 13 distinct peptides. Twelve peptides matched a predicted mouse protein similar to desmoplakin using a homolog search against the NCBI 
NR database. However, all 13 peptides were homologous to the human desmoplakin sequence. Of note, mouse peptide LLEAQIATGGIIDPK aligns to the 
coding sequence of human desmoplakin, but not to the annotated mouse desmoplakin gene.Genome Biology 2008, 9:R93
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mouse plasma. This initial release contains data derived from
568 LC-MS/MS runs of plasma fractions. A total of 13,779
distinct peptides have been identified with high confidence
and are included in this release, which can be searched and
downloaded. An important component comprises novel iso-
forms and transcript variants not previously predicted from
genome analysis that have been identified.
IPAS mapping of splice isoform variants for the MHC H2 K1 K geneFigure 4
IPAS mapping of splice isoform variants for the MHC H2 K1 K gene. Intact proteins were subjected to anion exchange (AX) and reverse phase (RP) 
chromatography fractionation. Each fraction was then subjected to tryptic digestion and LC-MS/MS analysis. Peptides derived from novel exons falling 
within the MHC 2 K1 K gene were identified. Spectral counts for matching peptides derived from this gene are plotted as a function of AX and RP 
fractionation. The color of each cell indicates the number of matching spectra: black = high; gray = medium; light gray = low; white = zero. (a) The 
distribution of spectra matching the major annotated splice isoform (ENSMUST00000025181). (b) The distribution of spectra matching the novel splice 
isoform (M17C4317_13_s2_e917_1_rf2_c1_n0|). (c) The distribution of spectra matching peptides found in both the major annotated splice isoform for 
this gene (ENSMUST00000025181) and the novel splice isoform (M17C4317_13_s2_e917_1_rf2_c1_n0|).
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Sample preparation and mass spectrometry analysis
The data for the mouse plasma PeptideAtlas was produced
from an initial set of four reference plasma samples. Each
represented a mixture of plasma from a mouse model of can-
cer and its matched control as presented in Table 2. All exper-
iments were carried out using the IPAS methodology [29].
Pooled plasma samples, immunodepleted of the abundant
proteins albumin, IgG, and transferrin using an Ms-3 column
(Agilent, Wilmington, DE, USA) were subjected to an exten-
sive two-dimensional fractionation schema using AX chro-
matography followed by RP chromatography, yielding
approximately 150 fractions per plasma pool. Each fraction
was subjected to in-solution digestion with trypsin followed
by LC-MS/MS analysis on either an LTQ-FT or LTQ-Orbitrap
mass spectrometer (Thermo-Finnigan, Waltham, MA, USA)
coupled to a nanoAcquity nanoflow chromatography system
(Waters, Milford, MA, USA).
Database searches and building the mouse plasma 
PeptideAtlas
Acquired data were automatically processed through the
Computational Proteomics Analysis System [35] pipeline.
The database search was initiated using the X!Tandem algo-
rithm [12] with the comet k-score module plug-in [36]. The
mouse IPI database [37], version 3.13, was used throughout
the project. All results of sequence searching were subse-
quently processed through PeptideProphet [10] for peptide
validation and quality control, using the Trans Proteomic
Pipeline [38], version 2.9.9. All identifications with a Peptide-
Prophet probability (P) 0.9 and above were combined to form
a master list of observed peptides across all four reference
sets. All experimental data were loaded into a proteomics
analysis database module under the Systems Biology Experi-
ment Analysis Management System [39]. The identified pep-
tide sequences were then mapped to the Ensembl mouse
release 43 proteome based on NCBI mouse genome build 36,
and the results were loaded into the PeptideAtlas relational
database [40,41].
ProteinProphet [13] was run on these reference data sets in a
combined mode for protein identification. Proteins with less
than 5% error rate from ProteinProphet were further charac-
terized with respect to tissue expression. Mouse GNF 1M
GeneAtlas, developed at the Genomics Institute of the
Novartis Research Foundation [15], was downloaded, and the
tissue with the maximum expression for a given gene was
assigned to that particular gene/protein. Subcellular location
and major functional network categorizations were based on
ingenuity pathway analysis [14].
Analysis of alternative splice isoforms
A target database, which had a total of 10,381,156 protein
sequences, was generated [22] as follows: cDNA sequences
from the ECgene database [21] and from the Ensembl mouse
database [11] were obtained in FASTA format; each sequence
set was translated separately in 3 reading frames and the first
instance of every protein sequence longer than 14 amino acids
was recorded; the sequences were combined and then filtered
for redundancy (preference was given to protein sequences
originating from an Ensembl transcript); and a collection of
common protein contaminants and reverse protein
sequences was appended to the sequence database. The for-
matted peak list files from each dataset were searched against
the target database using X!Tandem; peptides identified with
an X!Tandem expect value of <0.001 were extracted for fur-
ther analyses.
Protein peptide identifications to determine minimal 
covering sets
Many transcription units produce transcripts with multiple
splice isoforms that share exons. This often precludes assign-
ing a peptide as the translation product of a specific splice iso-
form. To avoid redundancy in analysis, protein identifications
were integrated to determine the minimum number of cover-
ing sets. A covering set is defined as a set of proteins contain-
ing all of the identified peptides. The minimal covering set is
the covering set with the smallest number of members.
Defining a minimal covering set is a nondeterministic polyno-
mial-time hard (NP hard) calculation, so exact definition of
the minimal covering set is not feasible for data sets of the size
found in protein/peptide identifications. Instead, we employ
a heuristic approach to find approximately optimal solutions.
Each member of the covering set of proteins is defined by a
'lead peptide'. The minimal covering set of proteins needed to
explain the observed peptide identification data was gener-
ated as follows: step 1, a list of peptides identified in all exper-
iments was created; step 2, the peptide list was ordered by the
number of spectra matching the peptide; step 3, the peptide
Table 2
Sources of plasma reference sets
Sample tag Sample ID Mouse model Strain Number of fractions analyzed Instrument
Pancreatic cancer and matched control 347 [42] Kras and INK/ARF FVB/n 163 Thermo LTQ-FT
Breast cancer and matched control 348 [43] Her2/Neu FVB 144 Thermo Orbitrap
Ovarian cancer and matched control 349 [44] LSL-K-rasG12D/+ PtenloxP/loxP LSL 144 Thermo LTQ-FT
Colon cancer and matched control 350 [45] D580 129/B6 117 Thermo LTQ-FT
Each set consisted of a pool of plasma from a mouse model of cancer and its matched wild-type control.Genome Biology 2008, 9:R93
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peptide'); step 4, a list of all proteins containing this peptide
was generated; step 5, the protein list was sorted by the
number of spectra matching peptides derived from the pro-
tein; step 6, the Ensembl protein having the largest number of
matching spectra was selected (in the event of ties, the protein
having the largest number of distinct peptides was selected; if
there were no Ensembl proteins in the list, the splice variant
with the largest number of spectra and distinct peptides was
selected); step 7, all peptides contained in this protein were
removed from the peptide list; step 8, the procedure was
repeated beginning with step 3 until no unassigned peptides
remained, thus generating a covering set of proteins that con-
tained all of the identified peptides. Each protein in the cov-
ering set contains at least one peptide that is unique to this
protein among all of the members of the covering set.
Abbreviations
AX, anion exchange; EGFR, epidermal growth factor recep-
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